'Warfarin' diaporamas de présentation

Toxicology Board Review I

Toxicology Board Review I. Ted Melnick, MD November 7, 2007. PEER 7 #16.

1.02k views • 69 slides

1.28k views • 51 slides

G. Camporese (Padova)

691 views • 49 slides

Jenelle Rogers VCH-PHC Pharmacy Resident 2009-2010

Anticoagulation post STEMI: warfarin for wall motion abnormality in the era of triple antithrombotics. Jenelle Rogers VCH-PHC Pharmacy Resident 2009-2010. Outline. Objectives Case Background Clinical Question Review of Literature Recommendations Follow-up Monitoring. Objectives.

433 views • 35 slides

WARFARIN

WARFARIN. AN OVERVIEW. HEMOSTASIS. VASCULAR SPASM PLATELET PLUG BLOOD COAGULATION GROWTH OF FIBROUS TISSUE IN CLOT. WHEN DOES BLOOD COAGULATE?. Procoagulants > Anticoagulants Injury to blood vessel Blood stasis. INITIATION OF BLOOD COAGULATION. Extrinsic Pathway. Intrinsic Pathway.

1.08k views • 27 slides

391 views • 26 slides

Non-Valvular Atrial Fibrillation An EPIDEMIC

Percutaneous Closure of the Left Atrial Appendage versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation: A Randomized Non-Inferiority Trial.

678 views • 25 slides

Cerebrovascular prevention in cardiac failure

Cerebrovascular prevention in cardiac failure. George Ntaios University of Thessaly, Larissa, Greece. Lausanne 6/09/2012. Stroke risk in cardiac failure. J Card Fail 2006; 12:39-46. Stroke risk increases with ?ejection fraction [ SAVE trial ]. N Engl J Med 1997; 336:251-7.

456 views • 25 slides

Antithrombotic therapy and oral surgery

Antithrombotic therapy and oral surgery. Michael B Streiff, MD FACP Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee ,National Comprehensive Cancer Network

679 views • 24 slides

Spotlight Case July 2005

Spotlight Case July 2005. Impatient Inpatient Dosing. Source and Credits. This presentation is based on the July 2005 AHRQ WebM&M Spotlight Case in Medicine See the full article at http://webmm.ahrq.gov CME credit is available through the Web site

423 views • 24 slides

Clinical Toxicology Case Presentation

1.33k views • 22 slides

364 views • 20 slides

Anticoagulation in Atrial Fibrillation

Anticoagulation in Atrial Fibrillation. Warfarin or Dabigatran. Discussing Anticoagulation in AF with Patients. What is atrial fibrillation? The back chamber has a pocket in which blood can stagnate and clot.

195 views • 18 slides

Predicting warfarin dosage from clinical data: A supervised learning approach

Predicting warfarin dosage from clinical data: A supervised learning approach. Presenter : CHANG, SHIH-JIE Authors : Ya -Han Hu , Fan Wu a, Chia-Lun Lo, Chun- Tien Tai b 2012.AIM. Outlines. Motivation Objectives Methodology Experiments Conclusions Comments. Motivation.

251 views • 16 slides

Warfarin and Dietary Interactions: Developing a Food and Drug Interaction Program

Warfarin and Dietary Interactions: Developing a Food and Drug Interaction Program. Rehana Jamali, Pharm.D. Associate Director, Pharmacy Services Brookdale Hospital and Medical Center Brooklyn NY May 2, 2009. Objectives.

1.07k views • 16 slides

230 views • 14 slides

Warfarin Survey

Warfarin Survey. November 2007. Study Sponsors. Massachusetts Medical Society Massachusetts Coalition for the Prevention of Medical Errors Massachusetts Association of Health Plans. Purpose. The specific goals of the study are to determine:

310 views • 13 slides

Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation

SPORTIF V Trial. Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation . Presented at American Heart Association Scientific Sessions 2003 Presented By Jonathan L Halperin, M.D. SPORTIF V Trial.

303 views • 6 slides

Apixaban Versus Warfarin in Patients with AF and ACS or PCI: The AUGUSTUS Trial

Apixaban Versus Warfarin in Patients with AF and ACS or PCI: The AUGUSTUS Trial. Exclusion Contraindication to DAPT Other reason for warfarin (prosthetic valve, mod/ sev MS). Inclusion AF (prior, persistent, or >6 hrs duration) Physician decision that oral anticoag is indicated

507 views • 4 slides

K Nakagawa et al. Nature 000 , 1 - 5 (2010) doi:10.1038/nature09464

MK-4 biosynthetic activity of UBIAD1 in Sf9 cells and effects of warfarin on MK-4 biosynthesis. K Nakagawa et al. Nature 000 , 1 - 5 (2010) doi:10.1038/nature09464.

78 views • 1 slides